The short answer
Sometimes, and it depends on which kind of insurance you have. As of October 2026, employer plans decide for themselves (in 2025, 43% of the largest employers covered GLP-1s for weight loss), Medicare covers Wegovy, Zepbound and Foundayo for eligible people through a temporary $50-a-month Bridge program that runs through December 31, 2027, and Medicaid coverage for weight loss depends on your state. Almost every route needs a prior authorization.
At GLP-1 SOS the coverage question comes up as often as any side effect, usually with frustration: the same drug is covered for a coworker and denied for you. That is not random. It depends on the type of insurance, the plan’s drug list and the reason the drug is prescribed. Here is how each route works as of October 2026, from official sources.
At a glance
Three routes, three rulebooks
1
Employer or private plan
Each plan chooses. Larger employers cover it more often, usually with prior authorization and sometimes a lifestyle program.
2
Medicare
Weight-loss drugs are excluded by law, but the temporary GLP-1 Bridge covers Wegovy, Zepbound KwikPen and Foundayo for $50 a month if you qualify.
3
Medicaid
Optional for states. KFF counted 13 state programs covering GLP-1s for obesity as of January 2026.
How coverage actually works
Employer plans set their own drug lists. In KFF’s 2025 Employer Health Benefits Survey, 16% of firms with 200 to 999 workers, 30% with 1,000 to 4,999 and 43% with 5,000 or more covered GLP-1s used primarily for weight loss, and 34% of covering firms required a dietitian, case manager or lifestyle program. Many large employers said use was higher than expected, so coverage can change at renewal, and losing it suddenly has after-effects of its own, covered in why you may feel not normal after quitting a GLP-1.
Medicare is different. By law, Part D plans cannot cover drugs used only for weight loss. To bridge that gap, CMS started the Medicare GLP-1 Bridge on July 1, 2026, and has extended it through December 31, 2027. It covers Foundayo, Wegovy (injection or tablet) and the Zepbound KwikPen for a $50 copay, outside the normal Part D benefit. You must be 18 or older and meet BMI and health criteria, and your prescriber must submit a prior authorization and certify a diet and exercise program. A broader Medicare plan, the BALANCE model, will not launch in 2027 as first planned.
Lab note
Coverage follows the diagnosis on the prescription as much as the drug in the box.
That diagnosis point matters everywhere. GLP-1s are also approved for type 2 diabetes, heart risk (Wegovy), sleep apnea with obesity (Zepbound) and a form of fatty liver disease (Wegovy). Plans that exclude weight loss may still cover those uses, which is why people with those conditions are not eligible for the Medicare Bridge. Medicaid must cover approved medical uses, but covering obesity is a state choice, and several states dropped it in late 2025 as budgets tightened.
From official sources, as of October 2026
The numbers that decide coverage
$50
monthly copay under the Medicare GLP-1 Bridge for eligible Part D enrollees, July 1, 2026 through December 31, 2027, per CMS
43%
of firms with 5,000 or more workers covered GLP-1s for weight loss in 2025, against 16% of firms with 200 to 999, per KFF
13
state Medicaid programs covering GLP-1s for obesity treatment as of January 2026, down from 16, per KFF
Sources: CMS, Medicare GLP-1 Bridge, July 2026; Medicare.gov; KFF Employer Health Benefits Survey, 2025; KFF, Medicaid Coverage of and Spending on GLP-1s, January 2026.
How to find out, and how to raise your odds
- Look up your plan’s formulary, not just the drug name. Search your insurer’s drug list for the exact product and note any prior authorization, step therapy or quantity limits. Wegovy.com and Zepbound.lilly.com also have coverage checkers.
- Ask what the prior authorization requires. Plans usually ask for your BMI, weight-related conditions and sometimes a diet program. Bring recent measurements and labs so your prescriber can submit a complete request.
- If you have Medicare, check the GLP-1 Bridge. Go to Medicare.gov/glp1bridge or call 1-800-MEDICARE. If you have type 2 diabetes, sleep apnea or fatty liver disease, ask your Part D plan instead; it may cover a GLP-1 for that use.
- If you have Medicaid, call your state program. Coverage for obesity treatment depends on your state and has been changing. Ask whether your state joined the BALANCE model, which can roll out to state Medicaid programs from May 2026 onward.
- Appeal a denial in writing. Ask for the reason and criteria, have your prescriber send a letter of medical necessity, and keep copies. If your employer excludes the drug, Novo Nordisk offers a sample letter for HR.
- Use the savings card only where it applies. With commercial coverage, the Wegovy and Zepbound savings programs can cut the copay to as little as $25 a month, with monthly and yearly caps. They exclude Medicare, Medicaid, TRICARE and VA.
- Plan for what no plan covers. Insurance pays for the drug, not for the routine that makes it easier to stay on. That is the gap GLP-1 SOS Daily Gut Relief was made for: 2 capsules with dinner with magnesium, ginger and peppermint to support regular bowel movements and digestive comfort.*
*GLP-1 SOS Daily Gut Relief supports regular bowel movements and digestive comfort. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Plan check
Good signs, and warning signs
Good signs
- The drug is on your formulary for weight management
- Published prior authorization criteria you meet
- You qualify for the Medicare Bridge
- Your diagnosis matches another approved use
Warning signs
- “Weight loss drugs” listed as a plan exclusion
- Your employer is reviewing the benefit at renewal
- A denial letter with no criteria named
- A seller offering “insurance-free” copies
Plans change every year. Recheck at open enrollment and before every renewal.
When to call your doctor
Talk to your prescriber, the same day if needed, when:
- Your coverage is ending and you have no plan yet
- You plan to switch to a compounded or online version to save money
- You restart after missing several doses; the labels may call for a lower dose
- You have severe belly pain that does not go away, or cannot keep liquids down
A coverage problem is solvable. Stopping suddenly without a plan is the costly mistake.
From the people behind the Lab
You do not have to figure this out alone.
GLP-1 SOS is the daily companion made for life on a GLP-1. Plain answers like this one, a support team that replies to real questions from real people, and daily formulas like GLP-1 SOS Daily Gut Relief, designed around the side effects that come with the medication. The GLP-1 Lab is our free education arm: no login, no paywall, no hype. Side effects are part of the road. Suffering through them is not.
Questions people also ask
Does Medicare cover Wegovy or Zepbound for weight loss in 2026?
Not through the normal Part D benefit, which excludes weight-loss drugs by law. But the temporary Medicare GLP-1 Bridge, running from July 1, 2026 through December 31, 2027, covers Wegovy (pen or pill), the Zepbound KwikPen and Foundayo for a $50 monthly copay if you meet the BMI and health criteria and your prescriber submits a prior authorization.
Why does my insurance cover Ozempic but not Wegovy?
Usually because of the reason it is prescribed. Ozempic is approved for type 2 diabetes, and a plan’s weight-loss exclusion does not apply to that use. Wegovy is approved for weight reduction and heart risk, and many plans exclude weight-loss drugs. If you have a condition such as heart disease, your plan may cover Wegovy for that use. Ask your insurer which diagnoses its criteria accept.
Does Medicaid cover GLP-1s for weight loss?
It depends on your state. Federal law lets state Medicaid programs choose whether to cover drugs for obesity, and KFF counted 13 states doing so as of January 2026, down from 16, after several states dropped coverage as budgets tightened. Medicaid must still cover GLP-1s for other approved uses, such as type 2 diabetes. Call your state Medicaid program to ask.
Can I use the Wegovy or Zepbound savings card with Medicare?
No. Both manufacturers exclude people on government insurance, including Medicare, Medicaid, TRICARE and VA, from their commercial savings cards. With Medicare, the route for weight loss is the GLP-1 Bridge, at $50 a month for eligible people. With commercial insurance that covers the drug, the cards can lower your copay to as little as $25 a month, with caps. For other approved uses, such as type 2 diabetes, ask your Part D plan.
What should I do if my insurance stops covering my GLP-1?
Do not stop suddenly without a plan. Ask your insurer for the reason in writing, have your prescriber file an appeal or a new prior authorization, and ask about covered alternatives, such as an oral option; see the oral GLP-1s compared. If you switch to a compounded version, read how compounded side effects differ first.
Sources (7)
- Medicare GLP-1 Bridge. Centers for Medicare & Medicaid Services, page last modified July 13, 2026.
- Weight loss drugs: Medicare GLP-1 Bridge coverage and eligibility. Medicare.gov, accessed October 2026.
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. KFF, updated May 11, 2026.
- Medicaid Coverage of and Spending on GLP-1s. KFF, January 16, 2026.
- Employer Health Benefits Survey 2025, Summary of Findings. KFF, October 2025.
- Wegovy cost and coverage information. Novo Nordisk, accessed October 2026.
- Zepbound savings and insurance options. Eli Lilly, accessed October 2026.
Reviewed by the GLP-1 SOS editorial team · Education, not medical advice · Talk to your prescriber about your dose and your symptoms.
